Characteristics of patients
| Characteristics . | . | Value . | . |
|---|---|---|---|
| Total no. of patients | 73 | ||
| Median age, y (range) | 51 (18-83) | ||
| Patients 60 y or older, n (%) | 26 (36%) | ||
| Males | 37 (51%) | ||
| Relative risk | Sokal35 | Hasford36 | |
| Low, n (%) | 33 (45%) | 29 (40%) | |
| Intermediate, n (%) | 30 (41%) | 43 (59%) | |
| High, n (%) | 10 (14%) | 1 (1%) | |
| Variant translocations | 10 (14%) | ||
| Clonal chromosome abnormalities in Ph+ cells, n (%) | 3 (4%) | ||
| Del9q+, n (%) | 7 (10%) |
| Characteristics . | . | Value . | . |
|---|---|---|---|
| Total no. of patients | 73 | ||
| Median age, y (range) | 51 (18-83) | ||
| Patients 60 y or older, n (%) | 26 (36%) | ||
| Males | 37 (51%) | ||
| Relative risk | Sokal35 | Hasford36 | |
| Low, n (%) | 33 (45%) | 29 (40%) | |
| Intermediate, n (%) | 30 (41%) | 43 (59%) | |
| High, n (%) | 10 (14%) | 1 (1%) | |
| Variant translocations | 10 (14%) | ||
| Clonal chromosome abnormalities in Ph+ cells, n (%) | 3 (4%) | ||
| Del9q+, n (%) | 7 (10%) |
All patients were enrolled within less than 6 months from diagnosis (median 1 month). Fifty-three patients (73%) received a short course of hydroxyurea before nilotinib.